GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, announced on October 27, 2026, that it has entered into an unsecured $1,000,000 Revolving Loan Agreement with Bowery Consulting Group Inc. The loan, dated October 23, 2026, carries a 12% annual interest rate and matures 12 months from issuance, with advances subject to the lender's approval. According to the press release distributed via NEWMEDIAWIRE, the agreement also led to significant changes to GeoVax's board of directors.
On the same day the loan was executed, five directors—Randal Chase, Dean Kollintzas, Nicole Lemerond, Jayne Morgan, and John Spencer, Jr.—resigned. Steven Brown, Tyler O’Brien, and Manpreet Uppal were appointed as their replacements, each nominated by the lender pursuant to the loan agreement. Following these changes, the board now consists of five directors. The board has determined that the newly appointed directors meet SEC and Nasdaq independence standards. O’Brien and Uppal will join the Audit Committee alongside Dr. Robert McNally. This restructuring gives the lender substantial influence over the company's governance, a notable development for a clinical-stage biotech.
David A. Dodd, Chairman and CEO of GeoVax, commented, “Securing this financing is an important achievement for GeoVax, reinforcing our balance sheet and providing the working capital needed to support our operations. I am pleased to welcome Steven, Tyler and Manpreet to our Board. Their diverse experience and strong leadership will bring fresh perspectives and valuable guidance as we continue to advance our GEO-MVA clinical program forward to what we believe will be an expedited pathway to commercialization.” Dodd also expressed appreciation to the departing directors.
The loan agreement includes customary representations, warranties, indemnification provisions, and conditions precedent to borrowing. Further details will be disclosed in a Form 8-K to be filed with the Securities and Exchange Commission. GeoVax’s priority program is GEO-MVA, a Modified Vaccinia Ankara-based vaccine targeting mpox and smallpox, which is advancing under an expedited regulatory pathway with a planned pivotal Phase 3 trial in late 2026. In oncology, the company is developing Gedeptin for head and neck cancer. For more information, visit www.geovax.com.
The implications of this announcement are multifaceted. The $1 million loan provides GeoVax with needed working capital to support its operations and advance its clinical programs, particularly GEO-MVA. However, the lender’s nomination of three directors—constituting a majority of the five-member board—raises questions about control and strategic direction. The board overhaul may signal a shift in priorities or increased lender influence over company decisions. Investors and stakeholders will be watching closely to see how the new board shapes GeoVax’s path forward, especially as the company prepares for a pivotal Phase 3 trial and seeks to commercialize its vaccine candidates. The loan’s 12% interest rate also reflects the cost of capital for a clinical-stage biotech. This development underscores the challenges and trade-offs facing small biotech companies as they seek financing to fund expensive clinical trials. The original release can be viewed on www.newmediawire.com.
